Female pelvic pain and dyspareunia · Single-group study · 2026
Can shockwave ease pelvic floor muscle pain in women?
In this study of 20 women, pain dropped from about 7 to about 2 out of 10, measured four weeks after four focused shockwave sessions. Scores for pelvic floor, bowel, bladder and prolapse symptoms also went down, by smaller amounts.
Improved over time- women with pelvic floor muscle pain
- 20
- sessions
- 4
- weeks of follow-up after treatment
- 4
Good to know: Based on clinic records, with no comparison group.
Wu YC, Ding DC BMC Women's Health, 2026 · Read the paper ↗
How this study worked
What happened
Pelvic pain
0–10 pain scale (middle value) · start and 4 weeks after treatment
Start4 weeks after treatment
Show the numbers
| Group | People | Start | 4 weeks after treatment |
|---|---|---|---|
| Focused shockwave | 20 | 7 | 2 |
The treatment
Focused shockwave
Focused, 4 sessions
- Sessions
- 4
- Pulses
- 2,000 per session · 500 at each of four spots around the vulva
- Strength
- 0.3–0.35mJ/mm² · 4 per second
- Numbing
- Not mentioned
- Device
- DUOLITH SD1 T-TOP
Compared with: No comparison group
Settings are what each study used, not a prescription.
Who took part
20 women treated at one clinic for pelvic floor muscle pain confirmed on examination.
Side effects
The study does not report side effects.
All the numbers and the full appraisal
The results, in numbers.
Twenty women with pelvic floor myofascial pain diagnosed by standardized pelvic examination, treated at one clinic July 2022–February 2024.
Retrospective single-arm pre/post cohort; full four-session protocol required for inclusion.
VAS, 0=no pain and 10=most severe pain1 reported outcome
Pain intensity (VAS)
VAS, 0=no pain and 10=most severe pain score; IQR reported, not SD
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused vulvar ESWT | 20 | 7 | 2 |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Within-person baseline to 4-week post-ESWT change; uncontrolled cohort
1 study · 20 participants in this estimate
Within-person baseline versus 4-week post-treatment
Wilcoxon signed-rank test
Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −5.0 (IQR 3.0); Wilcoxon effect r=−0.8796 (95% bootstrap CI −0.8878 to −0.8791).
Analysis details and source
Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 3.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.
PFDI-20; source does not state the total score range in the article text1 reported outcome
Pelvic Floor Disability Inventory-20
PFDI-20; source does not state the total score range in the article text PFDI-20; source does not state the total score range in the article text; median (IQR)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused vulvar ESWT | 20 | 33 | 26.5 |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Within-person baseline to 4-week post-ESWT change; uncontrolled cohort
1 study · 20 participants in this estimate
Within-person baseline versus 4-week post-treatment
Wilcoxon signed-rank test
Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −5.0 (IQR 9.5); r=−0.7319 (95% bootstrap confidence interval −0.8582 to −0.5297). Change did not uniformly reach MCID benchmarks from other populations.
Analysis details and source
Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 9.5. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.
POPDI-6, score 0–24; higher=worse1 reported outcome
Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6)
POPDI-6, score 0–24; higher=worse POPDI-6, score 0–24; higher=worse; median (IQR)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused vulvar ESWT | 20 | 11 | 8 |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Within-person baseline to 4-week post-ESWT change; uncontrolled cohort
1 study · 20 participants in this estimate
Within-person baseline versus 4-week post-treatment
Wilcoxon signed-rank test
Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −2.0 (IQR 5.0); r=−0.7158 (95% bootstrap confidence interval −0.8176 to −0.5992). No participants had objective prolapse; symptom scores do not imply anatomical prolapse.
Analysis details and source
Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 5.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.
CRADI-8, score 0–32; higher=worse1 reported outcome
Colorectal-Anal Distress Inventory-8 (CRADI-8)
CRADI-8, score 0–32; higher=worse CRADI-8, score 0–32; higher=worse; median (IQR)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused vulvar ESWT | 20 | 13 | 10 |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Within-person baseline to 4-week post-ESWT change; uncontrolled cohort
1 study · 20 participants in this estimate
Within-person baseline versus 4-week post-treatment
Wilcoxon signed-rank test
Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −1.0 (IQR 4.0); r=−0.5387 (95% bootstrap confidence interval −0.7890 to −0.1709).
Analysis details and source
Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 4.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.
UDI-6, score 0–18; higher=worse1 reported outcome
Urinary Distress Inventory-6 (UDI-6)
UDI-6, score 0–18; higher=worse UDI-6, score 0–18; higher=worse; median (IQR)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused vulvar ESWT | 20 | 10 | 9 |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Within-person baseline to 4-week post-ESWT change; uncontrolled cohort
1 study · 20 participants in this estimate
Within-person baseline versus 4-week post-treatment
Wilcoxon signed-rank test
Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −1.0 (IQR 3.0); r=−0.7014 (95% bootstrap confidence interval −0.8285 to −0.4845).
Analysis details and source
Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 3.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.
How treatment was delivered
DUOLITH SD1 T-TOP, F-SW probe; focused treatment perpendicular to upper/lower vulvar regions on both sides. 2,000 hits/session total (500 at each of four regions), EFD 0.3–0.35 mJ/mm², 4 Hz. The Abstract says once weekly for four consecutive weeks, while the Methods say ‘four consecutive treatments per week’; assessments were at baseline and at the 4-week follow-up (‘4 weeks after treatment’ in the Methods; ‘after 4 weeks of ESWT’ in the Abstract). No comparator or co-care is described.
Adverse events were collected by patient self-report and the investigator assessed their relation to ESWT (Methods), but the article reports no adverse-event results: no counts, no types and no statement that none occurred.
Small retrospective, single-center, uncontrolled cohort (n=20), subjective patient-reported endpoints, unblinded treatment/assessment, four-week follow-up, multiple comparisons without correction, and uncertain diagnostic generalizability. No natural-history or placebo comparison; observed changes may reflect expectation, fluctuation or regression to the mean.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Small retrospective, single-center, uncontrolled cohort (n=20), subjective patient-reported endpoints, unblinded treatment/assessment, four-week follow-up, multiple comparisons without correction, and uncertain diagnostic generalizability. No natural-history or placebo comparison; observed changes may reflect expectation, fluctuation or regression to the mean.
Source-linked critical reading
Retrospective single-cohort before-after study
Technical source record
Read article, case definition, treatment details, measurement definitions, raw Tables 1–3 and figure caption, median/IQR outcomes, Wilcoxon effects, limitations and discussion.
Scores improved four weeks after ESWT in this small group, but without a control the study cannot show that treatment caused the change or whether it lasts.
In women with pelvic floor myofascial pain, are pain and pelvic-floor symptom scores different four weeks after ESWT?
Retrospective single-center cohort of consecutive patients treated July 2022–February 2024; n=20 completed the four-session protocol.
Women with reproducible pelvic floor muscle tenderness/trigger points and characteristic pain; alternative structural causes excluded.
DUOLITH SD1 T-TOP focused F-SW probe, 2,000 hits/session across four bilateral vulvar regions, 0.3–0.35 mJ/mm², 4 Hz; four sessions. Text is ambiguous about exact session spacing.
No comparator or co-intervention is described.
Median VAS decreased 7.0 to 2.0; PFDI-20 33.0 to 26.5; POPDI-6 11 to 8; CRADI-8 13 to 10; UDI-6 10 to 9. Wilcoxon p values <0.01, <0.01, <0.01, <0.05 and <0.01, respectively.
Pre/post effect sizes r ranged −0.5387 to −0.8796. These are within-cohort associations; PFDI changes did not uniformly meet MCID thresholds derived from other populations.
No detailed ESWT harms table is presented.
Small, retrospective, unblinded, uncontrolled n=20, subjective scales, four-week follow-up, multiple uncorrected comparisons, potential expectation/natural fluctuation, and no external control.
Findings are preliminary and specific to women meeting this clinic’s PFMP case definition; they do not establish causality or durability.
Prospective controlled trials with longer follow-up, clear treatment spacing, prespecified outcomes and harms monitoring are needed.
Read the original article.
Effects of extracorporeal shockwave therapy on pain and pelvic floor function in women with pelvic floor myofascial pain: a retrospective cohort analysis.
Wu YC, Ding DC. · BMC women's health · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →